Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 3613505, 8 pages
https://doi.org/10.1155/2017/3613505
Research Article

LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model

1College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USA
2Northeast Ohio Medical University, Rootstown, OH 44272, USA
3Kent State University, Kent, OH 44240, USA
4CEL-SCI Corporation, 8229 Boone Blvd, Suite 802, Vienna, VA 22182, USA

Correspondence should be addressed to Ken S. Rosenthal; ude.namesor@lahtnesork

Received 21 November 2016; Revised 31 January 2017; Accepted 26 February 2017; Published 26 March 2017

Academic Editor: Bettahi Ilham

Copyright © 2017 Ken S. Rosenthal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Xu, G. K. Koski, M. Faries et al., “Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism,” Journal of Immunology, vol. 171, no. 5, pp. 2251–2261, 2003. View at Publisher · View at Google Scholar
  2. M. Croft, L. Carter, S. Swain, and R. Dutton, “Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles,” The Journal of Experimental Medicine, vol. 180, no. 5, pp. 1715–1728, 1994. View at Google Scholar
  3. S. Sad, R. Marcotte, and T. Mosmann, “Cytokine-induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting Th1 or Th2 cytokines,” Immunity, vol. 2, no. 3, pp. 271–279, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. Kemp and F. Ronchese, “Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity,” Journal of Immunology, vol. 167, no. 11, pp. 6497–6502, 2001. View at Publisher · View at Google Scholar
  5. A. Vacafloresa, S. N. Freedmana, N. M. Chapmana, and J. C. D. Houtman, “Pretreatment of activated human CD8 T cells with IL-12 leads to enhanced TCR-induced signaling and cytokine production,” Molecular Immunology, vol. 81, pp. 1–15, 2017. View at Publisher · View at Google Scholar
  6. S. Tugues, H. Burkhard, I. Ohs et al., “New insights into IL-12-mediated tumor suppression,” Cell Death and Differentiation, vol. 22, no. 2, pp. 237–246, 2015. View at Publisher · View at Google Scholar
  7. G. K. Koski, U. Koldovsky, S. Xu et al., “A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer,” Journal of Immunotherapy, vol. 35, no. 1, pp. 54–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Boggio, E. Di Carlo, S. Rovero et al., “Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice,” Cancer Research, vol. 60, no. 2, pp. 359–364, 2000. View at Google Scholar
  9. K. S. Rosenthal, P. Taylor, and D. H. Zimmerman, “J-LEAPS peptide and LEAPS dendritic cell vaccines,” Microbial Biotechnology, vol. 5, no. 2, pp. 203–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Parham, M. J. Androlewicz, N. J. Holmes, and B. E. Rothenberg, “Arginine 45 is a major part of the antigenic determinant of human â2-microglobulin recognized by mouse monoclonal antibody BBM1,” The Journal of Biological Chemistry, vol. 258, no. 10, pp. 6179–6186, 1983. View at Google Scholar
  11. D. Zimmerman, S. Morris, D. Rouse, K. Worthington, D. Elliott, and K. S. Rosenthal, “Immunization with peptide heteroconjugates primes a TH1 associated antibody (IgG2a) response which recognizes the native epitope on the 38 kDa protein of mycobacterium tuberculosis,” Vaccine Research, vol. 5, no. 2, pp. 103–118, 1996. View at Google Scholar
  12. P. R. Taylor, G. K. Koski, C. C. Paustian et al., “J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells,” Vaccine, vol. 28, no. 34, pp. 5533–5542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. R. Taylor, C. C. Paustian, G. K. Koski, D. H. Zimmerman, and K. S. Rosenthal, “Maturation of dendritic cell precursors into IL12 producing DCs by J-LEAPS immunogens,” Cellular Immunology, vol. 262, no. 1, pp. 1–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. S. Rosenthal, H. Mao, W. I. Horne, C. Wright, and D. Zimmerman, “Immunization with a L.E.A.P.S. heteroconjugate vaccine containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex type 1,” Vaccine, vol. 17, no. 6, pp. 535–542, 1998. View at Google Scholar
  15. N. Goel, Q. Rong, D. Zimmerman, and K. S. Rosenthal, “A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection,” Vaccine, vol. 21, no. 27–30, pp. 4410–4420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Boonnak, L. Vogel, M. Orandle, D. Zimmerman, E. Talor, and K. Subbarao, “Antigen-activated dendritic cells ameliorate influenza A infections,” The Journal of Clinical Investigation, vol. 123, no. 7, pp. 2850–2861, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. D. H. Zimmerman, K. F. Bergmann, K. S. Rosenthal, and D. A. Elliott, “A new approach to T cell activation: natural and synthetic conjugates capable of activating T cells,” Vaccine Research, vol. 5, no. 2, pp. 91–102, 1996. View at Google Scholar
  18. D. H. Zimmerman, J. P. Lloyd, D. Heisey et al., “Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain,” Vaccine, vol. 19, no. 32, pp. 4750–4759, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Cihakova, J. G. Barin, G. C. Baldeviano et al., “L.E.A.P.S heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart,” International Immunopharmacology, vol. 8, no. 5, pp. 624–623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. H. Zimmerman, P. Taylor, A. Bendele et al., “CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model,” International Immunopharmacology, vol. 10, no. 4, pp. 412–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. K. S. Rosenthal, K. Mikecz, H. Steiner et al., “Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis,” Expert Review of Vaccines, vol. 14, no. 6, pp. 891–908, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. T. A. Banks, S. Nair, and B. T. Rouse, “Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus,” Journal of Virology, vol. 67, no. 1, pp. 613–616, 1993. View at Google Scholar
  23. M. C. Hung and Y. K. Lau, “Basic science of HER-2/neu: a review,” Seminars in Oncology, vol. 26, Supplement 12, no. 4, pp. 51–59, 1999. View at Google Scholar
  24. P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis, “Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors,” Cancer Research, vol. 67, no. 3, pp. 1326–1334, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. N. Baxevanis, N. N. Sotiriadou, A. D. Gritzapis et al., “Immunogenic HER-2/neu peptides as tumor vaccines,” Cancer Immunology, Immunotherapy, vol. 55, no. 1, pp. 85–95, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Boggio, G. Nicoletti, E. Di Carlo et al., “Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice,” The Journal of Experimental Medicine, vol. 188, no. 3, pp. 589–596, 1998. View at Google Scholar
  27. B. Czerniecki, G. Koski, U. Koldovsky et al., “Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,” Cancer Research, vol. 67, no. 4, pp. 1842–1852, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. L. Knutson, K. Schiffman, M. A. Cheever, and M. L. Disis, “Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide results in short-lived peptide-specific immunity,” Clinical Cancer Research, vol. 8, no. 5, pp. 1014–1018, 2002. View at Google Scholar